News & Updates

Capivasertib, when added to fulvestrant, prolonged progression-free survival (PFS) by 4.1 months in an analysis of Chinese patients with hormone receptor–positive (HR+), HER2-negative (HER2– ABC) advanced breast cancer (ABC) whose disease had progressed on aromatase inhibitor, with or without a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor in the phase III CAPItello-291 trial.

A novel risk score, PAGED-B, may be used to predict hepatocellular carcinoma (HCC) development at the time of transition into hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB), suggests a study.

The incidence of hepatocellular carcinoma (HCC) remains low in patients with autoimmune hepatitis (AIH) even after developing cirrhosis, according to a study. Factors such as obesity, cirrhosis, and AIH/primary sclerosing cholangitis (PSC) variant syndrome can increase the risk of HCC incidence.